Gutenkunst RN

ORCID: 0000-0002-8659-0579 · 1 paper in corpus

nonrandomized-trial 2022

Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N-of-1 clinical trial

eLife ·doi:10.7554/elife.74510

BACKGROUND: Lymphatic malformations (LMs) often pose treatment challenges due to a large size or a critical location that could lead to disfigurement, and there are no standardized treatment approaches for either refractory or unresectable …